Prosecution Insights
Last updated: November 04, 2026
Application No. 18/667,014

PREPARING A FLEXIBLE DISPLAY SUBSTRATE WITH A MIXTURE OF TETRA ACIDS OR TETRA ACID DERIVATIVES AND POLYAMIC ACIDS

Final Rejection §102§103§112§DOUBLEPATENT
Filed
May 17, 2024
Examiner
FARAZDAGHI, ARMAN MAHMOOD
Art Unit
1762
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Akron Polymer Systems, Inc.
OA Round
2 (Final)
Grant Probability
Favorable
3-4
OA Rounds

Examiner Intelligence

Grants only 0% of cases
0%
Career Allowance Rate
0 granted / 0 resolved
-65.0% vs TC avg
Minimal +0% lift
Without
With
+0.0%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
22 currently pending
Career history
13
Total Applications
across all art units
This examiner has no resolved cases yet (career too new); statute-level performance unavailable. The Grant Probability card shows Tech Center averages instead.

Office Action

§102 §103 §112 §DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Response to Arguments The Applicant’s arguments filed September 15, 2026 in response to the previous claim objections with respect to claim 1 and rejections with respect to claims 1-16 under 35 U.S.C. 112(b) have been fully considered and are persuasive in view of the amended claims. The objection of claim 1 has been withdrawn. The rejectionof claims 1-16 under 35 USC § 112b has been withdrawn. The Applicant’s remaining arguments have been fully considered but are not persuasive The Applicant argues that MPEP 2113 is directed to product claims, not process claims. The Applicant states characterizing the origin of the polyamic acid is not a product-by-process” limitation in the sense of 2113 because the claim itself is a process claim. The previous Office action does not assert that the whole of claim 1 is a product claim; merely that the polyamic acid included in the claimed process is defined by a product-by-process limitation. This is effectively a product-by-process limitation nested within a method claim. The nesting of a product-by-process limitation within a method claim does not change the proper construction of the product-by-process limitation itself. For more information, see Purdue Pharma L.P. v. Epic Pharma, LLC, 811 F.3d 1345, 1353 (Fed. Cir. 2016); Biogen MA, Inc. v. EMD Serono, Inc., 976 F.3d 1326, 1334 (Fed. Cir. 2020). At present, limitations relating to polymerization of the polyamic acid are properly interpreted as product-by-process limitations. The Applicant may amend claim 1 to positively require additional method steps for polymerizing the indicated monomers within the currently nested product-by-process limitation. For example, the process may be amended to insert the following step after line 3 of claim 1 and delete the later product-by-process limitation: “...polymerizing 3,3’4,4’-biphenyltetracarboxylix dianhydride with an excess of p-phenylenediamine to form a polyamic acid; casting a solution of an aromatic tetracarboxylic acid or an aromatic tetracarboxylic acid derivative and [[a]] the polyamic acid in a polar organic solvent on a solid support in the form of a film, The Applicant argues that the Office’s interpretation improperly collapses the claim scope by equating the claimed polyamic acid with an “amine-terminated polyamic acid”. For clarification, the Office’s interpretation does not ignore the expected structure that would arise from the claimed product-by-process limitations. This is evident from the rejection of claim 1 under 35 U.S.C. 103 which finds that the previously cited Hwang teaches the reaction of 3,3’,4,4’-biphenyltetracarboxylic dianhydride (PBDA) with p-phenylenediamine (PPD). This reaction will result in the formation of a polyamic acid having the structure suggested by the monomers recited in claim 1. The rejection also makes clear that Hwang’s casting solution includes at least some tetracarboxylic acid derivative arising from ring opening of the BPDA by a polar solvent, reading on the structure claimed in claim 1. Thus, both the claim interpretation and prior art rejection address any structure associated with the claimed polyamic acid. The Applicant argues that the specification at paragraphs [0006] and [0024] of the specification provides a clear standard for interpreting the claimed polyamic acid. As acknowledged by the Applicant, paragraphs [0006] and [0024] describe a polyamic acid prepared using a 2 to 7% molar excess of PPD. This is significantly narrower than the product-by-process limitation in claim 1, which requires only an excess of PPD. Although the claims the are interpreted in light of the specification, the limitations from the specification are not read into the claims. See In re Van Geuns, 988 F.2d 1181, 26 USPQ2d 1057 (Fed. Cir. 1993). The Applicant also argues that the non-stoichiometric ratio would produce a polyamic acid with specific characteristics, not merely an “amine-terminated” polyamic acid. The office has met its initial burden of proof in showing that the polyamic acid employed in the claimed process appears to be the same as that of the prior art. This shifts the burden to the Applicant to bring forward evidence establishing a nonobvious difference between the product employed in the claimed process and the prior art. For more information, see MPEP 2113(II). The Applicant has alleged that the non-stoichiometric ratio would produce a polyamic acid with specific characteristics; however, the Applicant has not articulated with specificity as to what those characteristics are or how they would distinguish over the product taught by the prior art. The Applicant is invited to discuss the particular characteristics that would arise from the claimed product-by-process limitation and how those characteristics distinguish over the prior art of record. The Applicant argues that the Office has failed to establish that the prior art product “reasonably appears to be the same” as a polyamic acid obtained by polymerizing BPDA and an intentional excess of PPD. The Applicant argues that the claimed polyamic acid has a lower molecular weight and different chain-end composition than the equimolar polyamic acid of Hwang. The claims do not currently recite either a particular molecular weight or chain-end composition. Additionally, the previous Office action addressed the issue of the initially equimolar ratio of BPDA and PPD by noting that the molar amount of BPDA is reduced by reaction with the polar solvent (see page 6, section 13 of the non-final Office action dated 08/19/2026). After ring-opening of at least a portion of the BPDA, an equimolar relationship will no longer be present and would be expected to yield the same structure implied by the claimed product-by-process limitation. The Application argues that Hwang does not teach deliberate addition of an aromatic tetracarboxylic acid or derivative to a polyamic acid solution. The applicant acknowledges that Hwang includes a ring-opened dianhydride monomers but argues that these are formed in situ. While the Applicant’s motivation for including an aromatic tetracarboxylic acid or derivative may differ from that of Hwang (intentional versus incidental inclusion), it is not necessary that the prior art suggest the combination to achieve the same advantage or result discovered by applicant. For more information, see MPEP 2144(IV). The intent underlying Applicant’s addition of an aromatic tetracarboxylic acid or derivative is not sufficient to distinguish over the incidental aromatic tetracarboxylic acid or derivative explicitly disclosed by Hwang. The Applicant argues that the amended claims require that the R2 groups include at least one hydrogen and at least one alkyl group having 1-4 carbon atoms. This added limitation is addressed in the grounds of rejection below. Applicant’s attention is directed to pages 6-7, paragraphs 13 and 16 of the previous Office action below which establishes that Hwang’s ring-opened-BPDA are derivatives of 3, 3’, 4, 4’-biphenyltetracarboxylic acid (BPTA), with R2 groups of methyl and H from reacting with the solvents (water, N-methyl-pyrrolidone (NMP), and methanol). The Applicant acknowledges that ring-opened products of BPDA would be produced via Hwang’s teachings but argues that Hwang does not teach a compound with no less than 2 H groups and at least 1 one to four carbon alkyl. This structure would necessarily occur in the solution through ring-opening in the presence of methanol, NMP, and free water, whether “incidental” or not. Additionally, Hwang does disclose that this ring-opened derivative would necessarily occur during their process and be a compound with no less than 2 H groups (pg. 2, [0018]). As discussed above, the intent underlying Applicant’s addition of an aromatic tetracarboxylic acid or derivative is not sufficient to distinguish over the incidental aromatic tetracarboxylic acid or derivative explicitly disclosed by Hwang. The Applicant argues that Hwang does not teach polymerizing BPDA with an excess of PPD. While the Applicant acknowledges that some portion of BPDA in the initially equimolar combination will be consumed through ring-opening, the Applicant argues that the resulting incidental molar excess of PPD is distinct from the deliberate molar excess required by the claims, citing the molar excess disclosed in the instant specification. As discussed above, the intent underlying Applicant’s addition of an aromatic tetracarboxylic acid or derivative is not sufficient to distinguish over the incidental aromatic tetracarboxylic acid or derivative explicitly disclosed by Hwang. The Applicant argues that the Office’s anticipation analysis of claims 13, 15, and 16 improperly relies on inherency without establishing compositional identity. The Applicant asserts that the claimed composition and prior art composition are not the same. The point of distinction arises from Hwang’s incidental formation of an aromatic tetracarboxylic acid or derivative via ring-opening and the claimed method’s intentional addition of an aromatic tetracarboxylic acid or derivative. The Applicant’s arguments appear to focus on differences in intent rather than differences in structure. The previous Office action establishes that Hwang reads on the claimed process and employs materials identical to those recited in the claims. See pages 6-7, paragraphs 13-14. The Applicant argues that the process includes a separately added BPTA derivative. This distinction of “separately added” is not present in the claims, given the nested product-by-process language previously mentioned. Thus, the structure arising from the process of claim 1 and its dependents is reasonably expected to have the same properties as the structure arising the same process. The Applicant is invited to point out how the structure arising from Hwang’s incidental molar excess of PPD is distinct from the structure arising from the claimed excess of PPD. The Applicant argues that the present specification demonstrates unexpected results associated with films prepared from solutions including BPTA derivatives with exactly 2 H and 2 alkyl R2 groups The instant specification includes results associated with inventive Examples 1-7. The polyamic acid used in each of these examples is formed using NMP as a polar solvent and an approximately 1.28% molar excess of PPD (50.00 mmol PPD/[50.00 mmol PPD + 47.5 mmol BPDA] x 100 = 51.28 mol% PPD). In contrast, the claims are open to any polar solvent and any molar excess ranging from infinitesimally more PPD up to an unbounded upper limit. The claims are open to 2 or 3 R2 groups being hydrogen, whereas Examples 1-7 illustrate results only from 2 R2 groups being hydrogen. The claims are open to 1 or 2 R2 groups being an alkyl group having one to four carbon atoms, whereas Examples 1-7 illustrate results only for 2 R2 groups having either one or two carbon atoms. Whether unexpected results are the result of unexpectedly improved results or a property not taught by the prior art, the objective evidence of nonobviousness must be commensurate in scope with the claims which the evidence is offered to support. In other words, the showing of unexpected results must be reviewed to see if the results occur over the entire claimed range. See MPEP 716.02(d). Examples 1-7 are not reasonably commensurate in scope with the claims and therefore cannot be relied upon to establish non-obviousness for the entire claimed range. With respect to the rejection of claim 6 under 35 U.S.C. 103 as being unpatentable over Hwang, the Applicant argues that Hwang does not teach a two-step process involving initial formulation of a polyamic acid and subsequent addition of a tetracarboxylic acid or derivative as a separate component. The Applicant’s attention is directed to page 10, paragraphs 21-22 of the previous Office action and page 2, [0017-0019] of Hwang. The rejection of claim 6 finds that although not expressly disclosed by Hwang, it nevertheless would have been obvious to add a tetracarboxylic acid or derivative as a dilution monomer based on Hwang’s recognition that these monomers may be used to adjust the viscosity of the entire polyamic acid composition. Subsequent addition of a tetracarboxylic acid or derivative reads on the two-step process recited by claim 6. Regarding the rejection of claim 12 under 35 U.S.C. 103 as being unpatentable over Hwang in view of Hsieh, the Applicant argues that the rejection fails to properly support the obviousness combination. The Applicant points to the inclusion of the name “Miura” rather than Hsieh, arguing this clerical error introduces ambiguity into the stated rationale and fails to articulate a clear motivation to combine Hwang with Hsieh. The Applicant has correctly characterized this as a clerical error. The rejection accurately cited page and paragraph numbers corresponding to the Hsieh reference cited in the statement of the rejection at page 10, paragraph 23 of the previous Office action. Despite the clerical error, the rejection was sufficiently clear to communicate the basis for the rejection and to permit the Applicant to present arguments against the substance of the rejection. The Applicant argues that Hsieh merely teaches the fabrication of AMOLEDs on polyimide films and fails to cure the deficiency of Hwang with respect to the claimed composition. The Applicant’s arguments regarding any alleged deficiencies in Hwang have been addressed in full above. Regarding the nonstatutory double patenting rejection of claim 1 as being patentably indistinct of Application No. 18/609,254, hereafter ‘254, the Applicant argues that the restriction of the number of R2 groups to be “no less than 2” hydrogen and at least 1 “alkyl group having one to four carbon atoms” defines the derivative to have a partially esterified structure. Applicant points to the working examples of ‘254 using BPTA and argues that ‘254 does not teach or suggest the use of a derivative of BPTA having a partially esterified structure. Applicant’s attention is directed to page 2, line 1 of the claims of ‘254, where the use of hydrogen, alkyl, and their mixture are limitations for R2. This mixture of hydrogen and alkyl allows for the scheme presented in the instant application of a partially esterified BPTA derivative and therefore the instant’s claim of that structure falls within the scope of claim 1 of ‘254, making this limitation not patently distinct. Applicant argues that the instant claim produces an unexpected and superior result not suggested by ‘254. As discussed above, the objective evidence of nonobviousness must be commensurate in scope with the claims which the evidence is offered to support. In other words, the showing of unexpected results must be reviewed to see if the results occur over the entire claimed range. See MPEP 716.02(d). Instant examples 1-7 are not reasonably commensurate in scope with the claims and therefore cannot be relied upon to establish non-obviousness for the entire claimed range. The Applicant argues that the evaporation step claimed allows for a broader scope than ‘254, giving the example of ambient drying as something that falls within the instant claimed scope without being the scope of ‘254. In the previous Office action, this interpretation was articulated in (25). Despite amendment, this generic scope is read on by the specific scope of ‘254 and so the instant claim falls within the scope of claim 1 of ‘254. The claims are not patently distinct. The Applicant argues that the dependent claims inherit the distinctions of instant claim 1 and so are further distinguished. The Applicant’s arguments regarding any alleged patentable distinctions between the instant claim 1 and claim 1 of ‘254 have been addressed in full above. Claims 2-3, and 5-16 are not patently distinct of claims 3, 3, 4, 6, 6, 7, 7, 5, 5, 2, 9, 10, 11, and 12, respectively, of ‘254. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to ARMAN M. FARAZDAGHI whose telephone number is (571)270-5813. The examiner can normally be reached Monday - Friday, Monday - Thursday, 8:30 am - 5:00 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Robert Jones can be reached at (571) 270-7733. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ARMAN M. FARAZDAGHI/Examiner, Art Unit 1762 /ROBERT S JONES JR/Supervisory Patent Examiner, Art Unit 1762
Read full office action

Prosecution Timeline

May 17, 2024
Application Filed
Aug 19, 2026
Non-Final Rejection mailed — §102, §103, §112
Sep 15, 2026
Response Filed
Oct 30, 2026
Final Rejection mailed — §102, §103, §112 (current)

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
Grant Probability
Moderate
PTA Risk
Based on 0 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month